? A cooperative agreement has been announced by Illumina and Novogene on 15th of this month to jointly develop the Next Generation of Sequencing platform

Google Ventures is going to start off 2016 with $2.4 billion under management. This year, life sciences and health remained the most active area of investment

The note shows, Marr Bio’s revenues from January to June in 2015 is ￥8.77 million, and net profit is ￥1.67 million.

Aspire Capital is a growth equity firm focused on making direct investments into public companies across various industries.

BGI recently announced that it has cooperated again with PacBio, which is the leader of the real-time single-molecule sequencing technology (SMRT), to purchase Asia’s first Sequel sequencing system.

The National Institutes of Health announced that it aims to award $2 million in grant funding in fiscal year 2017 for research around new biomarkers to diagnose active pulmonary tuberculosis (TB)

The National Institutes of Health has announced that it will allocate further funding to support the refinement of molecular cancer diagnostics

Recently, Shenzhen iCubio Biomedical Technology Co., Ltd. was approved to list on the new OTC market and public transfer.

After months of hard work, the ‘PrecisionFDA’ project proposed by the U.S. Food and Drug Administration in August 5 this year, was announced to be open for use in December 15.Users

Roche today announced that it has signed a definitive agreement to acquire Kapa Biosystems, Inc. (Kapa) a privately-held company headquartered in Wilmington, Massachusetts, US.

Recently, domestic diagnostic manufacturer General Biologicals Corporation (GBC) announced that they have signed a strategic cooperation agreement with the United States genetic testing company Veritas Genetics.

The statistics presented that the VC/PE financing scale in internet industry for the second quarter of 2015 was $3.789 billion reduced 50.36% on link relative ratio with 222 quantity of financing cases

Roche will partner with SQZ Biotech to develop a cell therapy platform that would empower a patient’s own immune cells to fight a broad range of cancers, in an immuno-oncology collaboration that could generate more than $500 million for SQZ.

Illumina has made a strategic investment in Desktop Genetics (DTG) to advance DTG’s DESKGEN genome-editing software platform, the companies said today. The value of the investment was not disclosed.

Roche will join Pieris Pharmaceuticals in an up-to-CHF 415 million ($409 million) cancer immunotherapy collaboration designed to develop new drug candidates based on Pieris’